StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Down 54.3 %
GLMD opened at $6.90 on Friday. The business’s fifty day simple moving average is $3.90 and its 200 day simple moving average is $4.14. Galmed Pharmaceuticals has a 52 week low of $2.73 and a 52 week high of $23.80. The stock has a market cap of $34.81 million, a PE ratio of -2.88 and a beta of 0.67.
Galmed Pharmaceuticals Company Profile
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- How Much Can You Make in Stocks in One Month?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Start Investing in Real Estate
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.